|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | Cohort | | | | | | |
|  | DIVIDS | SAM | CICADA | NUSTART | STATT | CLHNS | Test |
| XX | 307 (14.5%) | 103 (4.9%) | 867 (40.9%) | 282 (13.3%) | 261 (12.3%) | 302 (14.2%) |  |
| Without EPI | 100 (84.7%) | 29 (34.9%) | 458 (55.9%) | 164 (68.0%) | 198 (80.2%) | 253 (86.9%) | <0.001 |
| Mild-Moderate EPI | 9 (7.6%) | 20 (24.1%) | 158 (19.3%) | 36 (14.9%) | 23 (9.3%) | 28 (9.6%) |  |
| Severe EPI | 9 (7.6%) | 34 (41.0%) | 204 (24.9%) | 41 (17.0%) | 26 (10.5%) | 10 (3.4%) |  |
| With EPI | 18 (15.3%) | 54 (65.1%) | 362 (44.1%) | 77 (32.0%) | 49 (19.8%) | 38 (13.1%) | <0.001 |
| Low Trypsinogen | 0 (.%) | 0 (.%) | 0 (0.0%) | 2 (2.9%) | 2 (2.3%) | 6 (6.0%) | 0.403 |
| Low Amylase | 0 (.%) | 99 (99.0%) | 782 (92.7%) | 245 (87.2%) | 231 (89.5%) | 296 (98.3%) | <0.001 |
| High Trypsinogen | 0 (.%) | 0 (.%) | 19 (90.5%) | 61 (88.4%) | 83 (96.5%) | 100 (100.0%) | 0.004 |